Valuation: Exelixis, Inc.

Market Cap 13.68B 12.02B 11.07B 10.3B 19.45B 1,302B 19.84B 133B 51.53B 638B 51.35B 50.23B 2,223B P/E 2026 *
17x
P/E 2027 * 14.6x
Enterprise Value 12.91B 11.34B 10.45B 9.72B 18.35B 1,229B 18.73B 125B 48.63B 602B 48.46B 47.4B 2,098B EV / Sales 2026 *
4.96x
EV / Sales 2027 * 4.09x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 day-0.83%
1 week+5.10%
Current month-0.83%
1 month+6.89%
3 months+25.81%
6 months+23.11%
Current year+23.11%
1 week 51.77
Extreme 51.77
55.91
1 month 48.1
Extreme 48.1036
55.91
Current year 39.71
Extreme 39.71
55.91
1 year 33.76
Extreme 33.755
55.91
3 years 18.64
Extreme 18.64
55.91
5 years 14.87
Extreme 14.87
55.91
10 years 7.93
Extreme 7.93
55.91
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap.
05-31Sell

Director

-9,812 0.0039%
05-31Sell

Director

-3,925 0.0016%
05-26Free

Director

8,367 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
-0.83%+5.10%+22.43%+182.37% 13.68B
-2.19%-2.39%+68.92%+123.30% 57.65B
+0.55%+17.77%+80.01%+100.93% 55.14B
+0.93%+3.64%-11.79%-12.98% 23.53B
+0.36%+4.75%+6.32%+407.11% 23.11B
-1.93%+11.11%+34.89%-7.86% 18.14B
+0.28%+5.36%+36.88%-30.23% 16.84B
+0.14%+9.60%+33.31% - 12.97B
-4.20%+0.19%+69.97%+122.68% 12.38B
+0.08%+6.56%+158.05%+161.37% 11.57B
Average -0.68%+5.65%+49.90%+116.30% 24.5B
Weighted average by Cap. -0.64%+4.71%+52.82%+116.38%

Financials

2026 *2027 *
Net sales 2.6B 2.28B 2.1B 1.96B 3.7B 248B 3.77B 25.27B 9.8B 121B 9.76B 9.55B 423B 2.92B 2.57B 2.37B 2.2B 4.16B 278B 4.24B 28.41B 11.01B 136B 10.97B 10.73B 475B
Net income 818M 719M 662M 616M 1.16B 77.93B 1.19B 7.96B 3.08B 38.2B 3.07B 3B 133B 934M 821M 756M 704M 1.33B 88.98B 1.36B 9.08B 3.52B 43.61B 3.51B 3.43B 152B
Net Debt -770M -677M -623M -580M -1.09B -73.34B -1.12B -7.49B -2.9B -35.95B -2.89B -2.83B -125B -1.73B -1.52B -1.4B -1.3B -2.46B -165B -2.51B -16.83B -6.52B -80.8B -6.5B -6.36B -281B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-07-01 US$53.96 -0.83% 1,843,235
26-06-30 US$54.41 +0.24% 2,599,397
26-06-29 US$54.28 -0.89% 2,587,750
26-06-26 US$54.77 +2.89% 6,931,468
26-06-25 US$53.23 +0.68% 2,256,253
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
54.41USD
Average target price
49.50USD
Spread / Average Target
-9.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock